DE60318447T2 - Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung - Google Patents

Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung Download PDF

Info

Publication number
DE60318447T2
DE60318447T2 DE60318447T DE60318447T DE60318447T2 DE 60318447 T2 DE60318447 T2 DE 60318447T2 DE 60318447 T DE60318447 T DE 60318447T DE 60318447 T DE60318447 T DE 60318447T DE 60318447 T2 DE60318447 T2 DE 60318447T2
Authority
DE
Germany
Prior art keywords
estrogen
group
estrogenic
estrogens
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60318447T
Other languages
German (de)
English (en)
Other versions
DE60318447D1 (de
Inventor
Herman Jan Coelingh Bennink
Evert Johannes Bunschoten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pantarhei Bioscience BV
Original Assignee
Pantarhei Bioscience BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience BV filed Critical Pantarhei Bioscience BV
Publication of DE60318447D1 publication Critical patent/DE60318447D1/de
Application granted granted Critical
Publication of DE60318447T2 publication Critical patent/DE60318447T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60318447T 2002-07-12 2003-07-11 Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung Expired - Lifetime DE60318447T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP02077812 2002-07-12
EP02077812 2002-07-12
EP03075435 2003-02-14
EP03075435 2003-02-14
PCT/NL2003/000513 WO2004006936A1 (fr) 2002-07-12 2003-07-11 Composition pharmaceutique comprenant des derives d'estetrol utilises dans la therapie anticancereuse

Publications (2)

Publication Number Publication Date
DE60318447D1 DE60318447D1 (de) 2008-02-14
DE60318447T2 true DE60318447T2 (de) 2009-01-02

Family

ID=30116907

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60318447T Expired - Lifetime DE60318447T2 (de) 2002-07-12 2003-07-11 Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung

Country Status (13)

Country Link
US (2) US9034854B2 (fr)
EP (1) EP1526856B1 (fr)
CN (1) CN100374116C (fr)
AT (1) ATE382356T1 (fr)
AU (1) AU2003253506A1 (fr)
CA (1) CA2492287C (fr)
CY (1) CY1107906T1 (fr)
DE (1) DE60318447T2 (fr)
DK (1) DK1526856T3 (fr)
ES (1) ES2299730T3 (fr)
PT (1) PT1526856E (fr)
SI (1) SI1526856T1 (fr)
WO (1) WO2004006936A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006936A1 (fr) * 2002-07-12 2004-01-22 Pantarhei Biosciences B.V. Composition pharmaceutique comprenant des derives d'estetrol utilises dans la therapie anticancereuse
DE102007032468A1 (de) * 2007-07-10 2009-01-15 Brätter, Christian, Dr. Transdermale Therapeutische Systeme, welche den Wirkstoff Anastrozol enthalten
MX341561B (es) 2011-06-01 2016-08-25 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
MX342537B (es) 2011-06-01 2016-10-04 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
EP2383279A1 (fr) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Procédé de préparation d'estetrol
WO2013034780A2 (fr) 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Procédé de préparation de l'estétrol et de composés analogues
CA2924255C (fr) 2013-09-18 2022-11-22 Crystal Pharma, S.A.U. Procede pour la preparation d'estetrol
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
HUE054551T2 (hu) * 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
NO3106148T3 (fr) 2015-06-18 2018-08-11
WO2016203009A1 (fr) * 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Comprimé orodispersible contenant de l'estétrol
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
ES2919626T3 (es) * 2018-05-02 2022-07-27 Estetra Sprl Régimen de tratamiento para el tratamiento de cáncer de mama avanzado positivo para el receptor de estrógenos
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2336433A1 (de) 1973-07-13 1975-04-03 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2426779A1 (de) 1974-05-31 1975-12-18 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336434A1 (de) 1973-07-13 1975-04-17 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4937238A (en) * 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JPH04235171A (ja) 1990-07-26 1992-08-24 Sumitomo Chem Co Ltd スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤
US5063507A (en) * 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344405C2 (de) * 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1996003929A1 (fr) 1994-08-04 1996-02-15 Biex, Inc. Procede de prediction d'un accouchement premature a l'aide d'estetrol (e4) comme indicatuer
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
ES2247710T3 (es) 1997-06-20 2006-03-01 Akzo Nobel N.V. Antagonista de gonadotropina.
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
JP2003527310A (ja) 1999-04-16 2003-09-16 イエナフアルム ゲーエムベーハー ウント ツェーオー． カーゲー エストロゲンを局部的に皮内投与するための医薬品組成物または化粧品組成物
US7273932B1 (en) 1999-05-28 2007-09-25 The University Of Cincinnati Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US20020012710A1 (en) * 1999-11-29 2002-01-31 Rimonest Ltd. Pomegranate products useful in improving health and methods of use thereof
EP1286664B1 (fr) 2000-05-12 2007-07-25 Oregon Health and Science University Combinaison de faibles doses d'oestrogene et d'agents immunotherapeutiques pour traiter les maladies immunitaires
WO2002030355A2 (fr) * 2000-10-11 2002-04-18 Laura Kragie Composition et procede destines a reduire les effets indesirables et/ou ameliorer l'efficacite d'agents inhibant l'aromatase
AU2002240949A1 (en) * 2001-03-21 2002-10-03 Schering Aktiengesellschaft Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
WO2002094276A1 (fr) 2001-05-18 2002-11-28 Pantarhei Bioscience B.V. Composition pharmaceutique a utiliser en therapie de remplacement d'hormones
EP1260225A1 (fr) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Compositions pharmaceutiques pour le traitement hormonal substitutif
WO2002100877A1 (fr) 2001-06-11 2002-12-19 Southwest Foundation For Biomedical Research Nouveaux analogues 2-alcoxyestradiol a activite antiproliferative et antimitotique
WO2004006936A1 (fr) * 2002-07-12 2004-01-22 Pantarhei Biosciences B.V. Composition pharmaceutique comprenant des derives d'estetrol utilises dans la therapie anticancereuse
CA2503549C (fr) * 2002-10-23 2012-07-10 Pantarhei Bioscience B.V. Compositions pharmaceutiques comprenant des derives d'estetrol a utiliser dans le traitement du cancer
ATE340580T1 (de) * 2003-05-22 2006-10-15 Pantarhei Bioscience Bv Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen

Also Published As

Publication number Publication date
CA2492287A1 (fr) 2004-01-22
AU2003253506A1 (en) 2004-02-02
US20150133413A1 (en) 2015-05-14
ATE382356T1 (de) 2008-01-15
US10201611B2 (en) 2019-02-12
DE60318447D1 (de) 2008-02-14
SI1526856T1 (sl) 2008-04-30
PT1526856E (pt) 2008-04-11
DK1526856T3 (da) 2008-03-10
US20060063723A1 (en) 2006-03-23
US9034854B2 (en) 2015-05-19
EP1526856A1 (fr) 2005-05-04
EP1526856B1 (fr) 2008-01-02
WO2004006936A1 (fr) 2004-01-22
CN100374116C (zh) 2008-03-12
CN1681513A (zh) 2005-10-12
ES2299730T3 (es) 2008-06-01
CY1107906T1 (el) 2013-09-04
WO2004006936A8 (fr) 2005-03-03
CA2492287C (fr) 2011-12-13

Similar Documents

Publication Publication Date Title
DE60318092T2 (de) Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
DE60216630T2 (de) Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
DE60209907T2 (de) Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen
DE60217324T2 (de) Pharmazeutische zusammensetzung für die hormonersatztherapie
DE69022722T2 (de) Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
US10201611B2 (en) Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
DE69433994T2 (de) Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
EP2552404B1 (fr) Forme galénique parentérale libérant des inhibiteurs de l'aromatase et des gestagènes, pour le traitement de l'endométriose
DE19739916C2 (de) Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
DE602004002591T2 (de) Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
DE69532894T2 (de) Verfahren zur empfängnisverhütung
DE3888269T2 (de) Hormon-Zusammensetzung und -Anwendung.
EP1084569B1 (fr) Androgenes en combinaison avec gestagenes pour compenser un deficit en testosterone chez l'homme et offrant simultanement une protection de la prostate
DE60309895T2 (de) Estrogenersatztherapie
DE60307602T2 (de) Kontinuierliche sulfatase-hemmende progestogen enthaltende hormonsubstitutions-therapie
DE60218881T2 (de) Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen
DE60223795T2 (de) Tetrahydroxyliertes Östrogen enthaltendes Arzneistoffverabreichungssystem zur Verwendung in der hormonalen Kontrazeption
WO1996019997A1 (fr) Composes a action antagoniste de la progesterone et anti×strogene utilisees conjointement pour la contraception feminine
DE60115274T2 (de) Verwendung von antiprogestinen zur prophylaxe und behandlung von hormonabhängigen erkrankungen
EP2123279A1 (fr) Administration séquentielle de 20,20,21,21,21-Ppentafluor-17-hydroxy-1 1bêta-[4-(hydroxyacétyl) phényl]-19-nor-17alpha-pregna-4,9-dien-3-on et un ou plusieurs gestagènes destinés au traitement de maladies gynécologiques
EP1100509A1 (fr) Utilisation de sulfamates d'oestrogenes biogenes pour l'hormonotherapie substitutive
EP0310542B1 (fr) Composés antigestagéniques et anti-oestrogéniques pour le traitement des tumeurs dépendant des hormones
DE602004009288T2 (de) Verwendung einer kombination eines aromatasehemmers, eines progestins und eines oestrogens zur behandlung von endometriose
EP1978970B1 (fr) Agent contraceptif
DE60121980T2 (de) Verwendung von 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-on zur herstellung eines medikaments zur behandlung von brust-, eierstock-, endometrium-krebs, myelom und meningiom

Legal Events

Date Code Title Description
8364 No opposition during term of opposition